system employing a sterile medical solution containing glucose or glucose polymers, for example nutritional solutions or solutions for peritoneal dialysis, whereby the majority of the solution is packed in a first package, while the glucose or the glucose polymers are separately packed in a second package, whereafter the two packages are heat sterilized. The content of the glucose or glucose polymers in the second package is maintained above 10% by weight, preferably above 20% by weight and most preferably in the order of 40% by weight in order to reduce or totally eliminate the breakdown of glucose. The medical solution after sterilization, mixing and diluting to 1.5% glucose content has an absorbency caused by breakdown products from glucose at 228 nm less than 0.35 and preferably in the order of 0.20 or lower. The medical solution is also defined in that after sterilization, mixing and dilution to 1.5% glucose content it has an ICG-value caused by breakdown products from glucose less than 50% and preferably less than 30%.
|
18. A method for providing a sterile medical solution comprising providing a first portion of a medical solution in a first heat-sterilizable package, providing a second portion of said medical solution in a second heat-sterilizable package, said second portion of said medical solution comprising glucose or a glucose polymer at a concentration of greater than about 20% by weight, said first portion of said medical solution being larger than aid second portion of said medical solution, heat sterilizing said first and second packages, and interconnecting said first and second packages following said heat sterilizing whereby said first and second portions of said medical solutions are combined while the formation of toxic substances during said sterilization is substantially prevented therein.
1. A system for providing a sterile medical solution comprising a first heat-sterilizable package containing a first portion of a medical solution, a second heat-sterilizable package containing a second portion of said medical solution comprising glucose or a glucose polymer at a concentration of greater than about 20% by weight, said first portion of said medical solution being larger than said second portion of said medical solution, and sterile connecting means for interconnecting said first and second packages whereby following sterilization of said first and second packages said first and second packages can be interconnected through said sterile connecting means and said first and second portions of said medical solutions can be combined while the formation of toxic substances during said sterilization is substantially prevented therein.
59. A system for providing a sterile medical solution suitable for peritoneal dialysis comprising a bag system having first and second separate compartments; said second compartment containing a second portion of said solution comprising glucose dissolved in water at a concentration of greater than about 20% and at a pH-value in the range of about 3 to 6; said first compartment containing a first portion of said solution comprising the remaining components for said solution including at least one component selected from the group consisting of sodium lactate, sodium chloride, potassium chloride, calcium chloride and magnesium chloride; said first portion of said medical solution being larger than said second portion of said medical solution; said bag system being heat sterilized at a temperature of greater than about 110°C while the glucose is prevented from forming toxic substances; and combining means for combining the contents of said first and second compartments in one of said compartments to form said sterile medical solution.
41. A method for providing a sterile medical solution suitable for peritoneal dialysis comprising the steps of providing a bag system having first and second separate compartments; providing in said second compartment a second portion of said solution comprising glucose dissolved in water at a concentration of greater than about 20% and at a pH-value in the range of about 3 to 6; providing in said first compartment a first portion of said solution comprising the remaining components for said solution including at least one component selected from the group consisting of sodium lactate, sodium chloride, potassium chloride, calcium chloride and magnesium chloride; said first portion of said medical solution being larger than said second portion of said medical solution; heat sterilizing said bag system at a temperature of greater than about 110°C while the glucose is prevented from forming toxic substances; and combining the contents of said first and the second compartments in one of said compartments to form said sterile medical solution.
69. A system for providing a sterile medical solution suitable for nutritional administration comprising a bag system having first and second separate compartments; said second compartment containing a second portion of said solution comprising glucose dissolved in water at a concentration of greater than about 20% and at a pH-value in the range of about 3 to 6; said first compartment containing a first portion of said solution comprising the remaining components for said solution including at least one component selected from the group consisting of sodium lactate, sodium chloride, potassium chloride, calcium chloride and magnesium chloride; said first portion of said medical solution being larger than said second portion of said medical solution; said bag system being heat sterilized at a temperature of greater than about 110°C while the glucose is prevented from forming toxic substances; and combining means for combining the contents of said first and second compartments in one of said compartments to form said sterile medical solution.
50. A method for providing a sterile medical solution suitable for nutritional administration comprising the steps of providing a bag system having first and second separate compartments; providing in said second compartment a second portion of said solution comprising glucose dissolved in water at a concentration of greater than about 20% and at a pH-value in the range of about 3 to 6; providing in said first compartment a first portion of said solution comprising the remaining components for said solution including at least one component selected from the group consisting of sodium lactate, sodium chloride, potassium chloride, calcium chloride and magnesium chloride; said first portion of said medical solution being larger than said second portion of said medical solution; heat sterilizing said bag system at a temperature of greater than about 110°C while the glucose is prevented from forming toxic substances; and combining the contents of said first and the second compartments in one of said compartments to form said sterile medical solution.
2. The system of
3. The system of
4. The system of
5. The system of
6. The system of
7. The system of
8. The system of
9. The system of
10. The system of
11. The system of
12. The system of
13. The system of
15. The system of
16. The system of
17. The system of
19. The method of
20. The method of
21. The method of
22. The method of
23. The method of
24. The method of
25. The method of
26. The method of
27. The method of
28. The method of
29. The method of
30. The method of
31. The method of
32. The method of
33. The method of
34. The method of
35. The method of
36. The method of
37. The method of
40. The method of
42. The method of
43. The method of
44. The method of
45. The method of
46. The method of
47. The method of
48. The method of
49. The method of
51. The method of
52. The method of
53. The method of
54. The method of
55. The method of
56. The method of
57. The method of
58. The method of
60. The system of
61. The system of
62. The system of
63. The system of
64. The system of
65. The system of
66. The system of
67. The system of
68. The system of
70. The system of
71. The system of
72. The system of
73. The system of
74. The system of
75. The system of
76. The system of
77. The system of
78. The system of
|
The present invention relates to a system employing a sterile medical solution comprising glucose or glucose-like compounds, for example nutritional solutions or solutions for peritoneal dialysis, whereby the majority of the solution is packed in a package whilst the glucose or the glucose-like compounds are packed separately in a second package, whereafter the two packages are heat sterilized. By the expression glucose-like compounds is meant for example glucose polymers.
It is known to pack a CAPD-solution in a two chamber package from, for example, the article "In Vitro Testing of a Potentially Biocompatible Continuous Ambulatory Peritoneal Dialysis Fluid" by N Topey et al, in Nephrol Dial Transplant (1991) 6:574-581.
The same, or at least a similar, two chamber package having essentially the same inventors is described in international patent application no. WO 91/08008. From e.g. Example 1 of this document it is apparent that the two parts of the package are intended to contain essentially the same quantity of solution. Thus, when the article refers to a larger and smaller package respectively, this is assumed to mean that even in this case the two packages will contain the same quantity of solution, though with the one package being made larger so as to be able to serve as a mixing chamber.
It is known from, for example, the article "Toxity of peritoneal dialysis fluids on cultured fibroblasts L-929" by Anders Wieslander et al, in Kidney International, Vol 40 (1991) pp 77-79, that heat sterilized CAPD-solutions can contain harmful components which can depend on the decomposition of certain compounds, for example glucose, during the sterilization,
It is known from, for example, U.S. Pat. Nos. 4,369,779; and 4,753,697 to achieve a sterile coupling between two tubes in various ways, which can be joined to two separate packages.
The present invention can be said to be a development of the above mentioned teachings and relates to a system making use of a sterile medical solution comprising glucose or glucose-like compounds, for example nutritional solutions or solutions for peritoneal dialysis, whereby the majority of the solution is packed in a package whilst the glucose or the glucose-like compounds are separately packed in a second package, whereafter the two packages are heat sterilized.
The system according to the invention is characterized in that the content of the glucose or glucose-like compounds in the second package is maintained above 10% by weight, suitably above 20% by weight, and preferably in the order of 40% by weight. In this manner the breakdown of the packaged product is reduced. At the same time the risk of breakdown is reduced since the product which is sensitive to breakdown need not be in contact with all the compounds in the final solution during heat sterilization.
A further advantage with the invention is the possibility to achieve a final neutral solution with a pH between 6.5 and 7.5. Preferably, a pH of 7.0 is hereby achieved. Here it should be stressed that as far as we are aware no such neutral solutions for PD-dialysis are presently commercially available on the market.
In practice, it has been shown to be possible to make use of a sterilizing temperature between 110°C and 150°C and sterilizing times between 180 minutes and 10 minutes from the commencement of heating to cooling to room temperature. At the same time the time interval for the maximum heating should hereby be kept as short as possible, though sufficiently long, of course, to meet the requirements imposed by the authorities so that sufficient death rate of bacteria and spores is obtained.
One possibility is that the two packages are manufactured separately and each one provided with a connection piece or connection tube. Preferably, both packages are completely sealed and each one provided with a connection piece or connection tube made from a heat sealable material and sealed at its extremity with a welded seal, which is intended to be removed or opened under maintained sterility for connection of the two packages together and mixing of their contents. Equipment and procedure for such a connection is described in the above mentioned American patents which are therefore included in the present description. The invention does however also include other known or future sterile connections, for example such as those which are nowadays used for CAPD. An advantage with this embodiment is that the smaller package can be separately heat sterilized at a high temperature for a short period with a short heating period and a short cooling period.
Alternatively, the second package containing said glucose or glucose-like compounds can form a minor part of a double package, for example a double bag, the other part of which forms the first package. The two parts can then be made to communicate with each other for mixing of the contents. The first package should thereby have such volume that in addition to its original contents, it can also accommodate the contents of the second package. An advantage with this embodiment is that an openable connection conduit can be arranged between the two packages already during their manufacture. The heating up time for the smaller package will however be somewhat dependent on the heating up time of the larger package. Even in this case, however, it is desirable that the sterilisation temperature is kept high and the heating up time short.
Suitably, the contents of the smaller glucose-containing package are maintained at a low pH during sterilisation, preferably in the order of 3.5. At the same time, the contents of the two packages during sterilisation should be maintained with such respective pH-values that the final resultant product after mixing is substantially neutral, i.e. with a pH between, for example, 6.5 and 7.5, preferably about 7∅
The invention further relates to a solution intended for a system of the above defined type. This solution is characterized in that, after sterilization, mixing and diluting to 1.5% glucose content, it has an absorbency caused by breakdown products from glucose at 228 nm of less than 0.35 and preferably 0.20 or lower.
Where the solution according to the invention is intended for peritoneal dialysis the system according to the invention can comprise a smaller package containing 20-500 ml, preferably approximately 65-75 ml glucose with a pH of approximately 3-6, preferably approximately 3.5 and a glucose content of 10-70%, preferably approximately 40%, as well as a larger package containing the remaining compounds, for example Na-lactate 9 g, NaCl 10.8 g, CaCl2 380 mg and MgCl2 102 mg, with a pH adjusted to a desired value between 6 and 8.5, and preferably distilled water in a quantity in the order of 2 liters, for example 1935-1925 ml.
The solution according to the invention can also be defined in such a manner that, after sterilization, mixing and diluting to 1.5% glucose content, it has an ICG-value (Inhibition of Cell Growth tested on cultured fibroblasts L-929) caused by breakdown products from glucose of less than 50%, preferably less than 30%. The reason for this definition is, as can be seen from FIG. 4, that the degree of inhibited cell growth bears a close relation to the UV-absorbency at 228 nm. It must however be taken into consideration that the solution should not contain compounds other than glucose or glucose-like compounds with absorbency at 228 am. Should the solution contain other such compounds, then the absorbency will be affected. With knowledge of the included compounds it can however be calculated how much of the absorbency is dependent on breakdown products from glucose.
FIG. 1 shows a double package intended to be used in connection with the system according to the invention.
FIG. 2 shows an alternative in the form of two separate bags.
FIG. 3 illustrates the relationship between the glucose content and the ICG-value after heat sterilising of glucose dissolved in pure water.
FIG. 4 shows the relationship between the ICG-value and the UV-absorbency at 228 nm after heat sterilizing solutions having different glucose content in pure water.
FIG. 5 show the absorbency at 228 nm after heat sterilizing solutions with different glucose contents in pure water.
FIG. 6 shows in the form of a bar chart a comparison between the ICG-values after heat sterilizing water solutions with 1.5% and 40% glucose respectively.
FIG. 7 illustrates in the same manner a comparison between the absorbency at 228 nm after heat sterilizing water solutions with 1.5% and 40% glucose respectively.
From the above mentioned article by Anders Wieslander et al it is apparent that existing commercial glucose solutions inhibit the growth of cultured fibroblasts. This implies that the glucose solutions contain one or more substances which are toxic in the biological system.
From a comparison of, for example, sterile filtered solutions and heat sterilized solutions with essentially the same contents, it appears that the toxic effect depends on the substances formed in connection with the heat sterilization or the subsequence storage. Here it should be noted that the authorities in many countries require a sterilization after packaging of the product. In principle this is not possible with sterile filtered solutions.
From, for example, the graph in FIG. 4 it can be seen that the toxic effect (percentage inhibited growth), and thereby also the quantity of toxic substances, is related to the absorbency at 228 nm. This implies that a glucose solution with low absorbency is, from a toxicological view, probably better than a solution with high absorbency at 228 nm.
The aim has been to provide a glucose solution with a considerably lower toxic effect on the biological system compared with sterile glucose solutions commercially available until now. By low toxicity is meant that, accordingly to the invention, a glucose solution diluted to a glucose content of 1.5% may not inhibit cell growth of cultured fibroblasts L-929 through breakdown products (tested according to the above mentioned article by Anders Wisslander et al by more than 50% and preferably by not more than 30%.
Two alternative bag systems are shown in FIGS. 1 and 2 which can form the above mentioned packages. In FIG. 1 a double bag is shown consisting of a larger part A and a smaller part B which are separated by a weld or other seal C. The ends of the double package are sealed in a similar manner by welds or other means D, E respectively. The weld C can be entirely broken open. Alternatively, the two bag parts A and B can be connected already during manufacture by means of a tube F containing a suitable breakable seal, for example a conventional breakpin.
The alternative shown in FIG. 2 consists of a separate larger bag A and a similarly separate smaller bag B. The two bags are provided with connection pieces or connection conduits denoted by G and H respectively. Each of these connection pieces can be provided with sterile connecting halves for sterile connection. In the shown example it is intended that they be terminated with an end sealing weld I, J respectively. A sterile connection can thus be achieved in the manner described by way of example in said above mentioned U.S. Pat. Nos. 4,369,779 and 4,753,697, the subject matter of which is incorporated herein by reference. The contents of these are therefore included in the present description.
The alternative according to FIG. 2 enjoys the advantage that the bag A can be heat sterilized in a conventional manner at the same time that a particularly quick heating and cooling of the bag B can be achieved if it is manufactured from two plastic sheets laid one on top of the other which are joined to each other along the periphery and which have dimensions such that the layer of glucose solution can be maintained relatively thin during the heat sterilization. By way of example, a bag containing 75 ml of glucose solution can have the dimensions 10 cm by 10 cm.
The larger bag A can, if used in peritoneal dialysis, contain a salt solution with the contents Na-lactate 9 g, NaCl 10.8 g, CaCl2 380 mg and MgCl2 102 mg (the composition can be varied somewhat). The pH should be adjusted to the desired value between 7 and 9. Finally, the bag preferably contains distilled water in a quantity in the order of 2 liters, for example 1925-1935 ml. The heat sterilization is envisaged to take place in a conventional manner in an autoclave with suitably adapted time and temperatures.
The small bag B can contain glucose concentrate, for example 20-500 ml, preferably 65-75 ml, 10-70% glucose, preferably 40%. The pH-value should lie between 3 and 6, preferably about 3.5. The sterilization may be effected in a autoclave at a temperature between 110°C and 145°C, suitably above 120°C and preferably at 130°C With the embodiment according to FIG. 1 the bag part B is of course sterilized at the same time as the bag part A. With the embodiment according to FIG. 2, the bag B is however suitably sterilized separately so that the necessary sterilizing temperature can be quickly reached and thereafter obtain a quick cooling.
During the trials F0 equal to 40 was sought, though in practice this value varied somewhat. By F0 is meant the time in minutes which the solution should need to be maintained at 121°C in order to become sterile in accordance with that which is demanded by supervising authorities. F0 equal to 10 implies therefore that the product must be maintained at 121°C for 10 minutes in order to achieve sterility.
The following table presents the results of a number of experimental tests. In line 1 a sterile-filtered, i.e. non-heat sterilized, complete solution for PD containing 1.5% glucose was tested. The three following lines show the results with heat sterilization with differing F0 of a complete PD-solution in which the glucose was added at the beginning. These solutions also included 1.5% glucose.
The last three lines give the results of tests on complete mixing with which a glucose solution was heat sterilized separately so that first after sterilizing it could be mixed with remaining compounds included in the PD-solution. The glucose concentration was hereby maintained during the sterilizing at about 40%. After the mixing together, this was reduced to 1.5% in agreement with the concentration of remaining solutions in the comparative tests.
From the table it can further be seen that with help of the invention the concentration of acetaldehyde can be kept low by separately sterilising the glucose solution. Acetaldehyde is a typical breakdown product from glucose and the amount of this product should be kept below 1.0 ppm, suitably below 0.1 ppm and preferably in the order of 0.01-0.001 ppm.
In FIG. 4 the relationship is shown between the absorbency at 228 nm and the ICG-values after heat sterilising of a number of glucose solutions in pure water. The graph shows that the condition for an acceptable product can either be defined by means of a low absorbency value or low ICG-value.
FIG. 5 shows the absorbency at 228 nm after heat-sterilising for a number of glucose solutions in pure water. The higher the glucose concentration is maintained, the lower the absorbency and thus also the ICG-value becomes. In practice, however, the glucose concentration should not be maintained above about 40%. In addition, particularly at low temperatures there is a risk of crystal-formation.
Finally, FIGS. 6 and 7 show respectively a comparison between the absorbency values at 228 nm for a sterilized water solution with 1.5% glucose in complete condition and a corresponding 1.5% solution in which the glucose was sterilized separately at a concentration of 40%.
The invention has been described in the above particularly in connection with peritoneal dialysis, more particularly CAPD. It will however be apparent that the invention can also be suitable in connection with other sterile solutions containing glucose or glucose-like compounds, for example polymers of glucose. By way of example the invention can be suitable in connection with sterilization of nutritional solutions containing glucose or glucose-like compounds which otherwise will be problematic in terms of breakdown products in connection with heat sterilization.
Table
The toxicity and breakdown products in PD-solutions after heat sterilizing. The PD-solutions were sterilized either as a conventional bag or double bag with glucose concentrate. All values refer to finally mixed end products.
______________________________________ |
Acet- Cyto- |
alde- Form- toxi- |
Absorbency hyde aldehyde city |
Test solution |
F0 |
228 nm 284 nm ppm ppm % |
______________________________________ |
Sterile- 0 0.295 0.011 0.005 <0.005 16 |
filtered |
Complete 10 0.467 0.053 4.0 0.005 44 |
Complete 20 0.666 0.110 8.8 0.005 73 |
Complete 30 0.765 0.150 11.6 0.2 83 |
Glucose conc |
10 0.404 0.074 0.005 <0.005 21 |
Glucose conc |
20 0.419 0.112 0.005 <0.005 25 |
Glucose conc |
30 0.414 0.158 0.005 <0.005 27 |
______________________________________ |
Wieslander, Anders, Jonsson, Sven, Kjellstrand, Per, Martinson, Evi, Svensson, Eva, Andren, Anders
Patent | Priority | Assignee | Title |
10705044, | Dec 21 2015 | ENDRESS+HAUSER CONDUCTA GMBH+CO. KG | Inline sensor arrangement and method for commissioning same |
10842714, | Oct 14 2010 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter chamber diffuser |
11779519, | Oct 14 2010 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
5593396, | Mar 18 1993 | CONVATEC TECHNOLOGIES INC | Bag for containing liquid |
5824216, | May 11 1994 | Fenwal, Inc | Blood collection container |
5989237, | Dec 04 1997 | Baxter International Inc | Sliding reconstitution device with seal |
6019750, | Dec 04 1997 | BAXTER INTERNAIONAL INC | Sliding reconstitution device with seal |
6022339, | Sep 15 1998 | Baxter International Inc | Sliding reconstitution device for a diluent container |
6051194, | Jun 12 1995 | California Institute of Technology | TI02-coated fiber optic cable reactor |
6063068, | Dec 04 1997 | Baxter International Inc | Vial connecting device for a sliding reconstitution device with seal |
6071270, | Dec 04 1997 | Baxter International Inc | Sliding reconstitution device with seal |
6090091, | Dec 04 1997 | Baxter International Inc | Septum for a sliding reconstitution device with seal |
6090092, | Dec 04 1997 | BAXTER INTERNATIONAL, INC | Sliding reconstitution device with seal |
6113583, | Sep 15 1998 | Baxter International Inc | Vial connecting device for a sliding reconstitution device for a diluent container |
6159192, | Dec 04 1997 | Baxter International Inc | Sliding reconstitution device with seal |
6241943, | Feb 20 1996 | Fresenius Medical Care Deutschland GmbH | Use of a solution comprising glucose for peritoneal dialysis having reduced formation of age products |
6309673, | Sep 10 1999 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
6475529, | Sep 10 1999 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
6582415, | Sep 15 1998 | Baxter International Inc | Sliding reconstitution device for a diluent container |
6610040, | Dec 04 1997 | Baxter International Inc | Sliding reconstitution device with seal |
6663829, | Oct 23 1998 | Gambro AB | Method and apparatus for reducing the degradation of heat sensitive components in medical substances during heat sterilization |
6712202, | Aug 23 2000 | Fresenius Kabi Deutschland GmbH | Method for producing a two-chamber arrangement, and such a two-chamber arrangement |
6852103, | Dec 04 1997 | Baxter International Inc. | Sliding reconstitution device with seal |
6875203, | Sep 15 1998 | Baxter International Inc | Vial connecting device for a sliding reconstitution device for a diluent container |
6890328, | Sep 15 1998 | Baxter International Inc. | Sliding reconstitution device for a diluent container |
7011855, | Jul 01 1994 | Baxter International Inc. | Biochemically balanced peritoneal dialysis solutions |
7053059, | Jul 25 2003 | Baxter International Inc; BAXTER HEALTHCARE S A | Dialysis solutions with reduced levels of glucose degradation products |
7074216, | Sep 15 1998 | Baxter International Inc | Sliding reconstitution device for a diluent container |
7122210, | Jan 11 2002 | NIKKISO CO , LTD | Bicarbonate-based solutions for dialysis therapies |
7208479, | Dec 04 1998 | Baxter International, Inc. | Peritoneal dialysis solution containing modified icodextrins |
7358505, | Sep 15 1998 | Baxter International Inc | Apparatus for fabricating a reconstitution assembly |
7371345, | Dec 23 2002 | Ethicon, Inc | Sterilization of medical adhesive kits |
7425209, | Sep 15 1998 | Baxter International Inc | Sliding reconstitution device for a diluent container |
7445801, | Jun 07 2002 | BAXTER INTERNATIONAL, INC ; BAXTER HEALTHCARE S A | Stable bicarbonate-based solution in a single container |
7641851, | Dec 23 2003 | Baxter International Inc | Method and apparatus for validation of sterilization process |
7678097, | Nov 12 1999 | Baxter International Inc | Containers and methods for manufacturing same |
7722594, | Jun 02 2004 | Laboratoire Aguettant | Infusion bag with integrated rinsing system |
7790102, | Dec 10 2002 | Gambro Lundia AB | Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
7837666, | Jan 28 2005 | FRESENIUS MEDICAL CARE HOLDINGS, INC | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
7935070, | Jan 28 2005 | FRESENIUS MEDICAL CARE HOLDINGS, INC ; Fresenius Medical Care North America | Systems and methods for dextrose containing peritoneal dialysis (PD) solutions with neutral pH and reduced glucose degradation product |
7938816, | Jun 02 2004 | Laboratoire Aguettant | Infusion bag with integrated rinsing system |
7985212, | Jan 28 2005 | FRESENIUS MEDICAL CARE HOLDINGS, INC | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
8022375, | Dec 23 2003 | Baxter International Inc. | Method and apparatus for validation of sterilization |
8052631, | Jan 28 2005 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
8226627, | Sep 15 1998 | Baxter International Inc. | Reconstitution assembly, locking device and method for a diluent container |
8328784, | Jan 28 2005 | FRESENIUS MEDICAL CARE HOLDINGS, INC | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
9180069, | Jan 28 2005 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions |
9585810, | Oct 14 2010 | FRESENIUS MEDICAL CARE HOLDINGS, INC | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
9918999, | Dec 10 2002 | Gambro Lundia AB | Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
9962896, | Feb 27 2008 | Fenwal, Inc. | Peelable seals including porous inserts |
Patent | Priority | Assignee | Title |
3874384, | |||
4368729, | Oct 14 1980 | BAXTER INTERNATIONAL INC , A CORP OF DE | Aseptic system for total parenteral nutrition and the like |
4369779, | Jul 11 1980 | E. I. du Pont de Nemours and Company | Sterile docking process, apparatus and system |
4657540, | Jun 12 1981 | Terumo Corporation | High pressure steam sterilized plastic container holding infusion solution and method for manufacturing the same |
4994057, | Sep 24 1987 | Pall Corporation | Sterilizable system for blood storage |
4997083, | May 29 1987 | VIFOR MEDICAL AG SWISS COMPANY | Container intended for the separate storage of active compositions and for their subsequent mixing |
5114004, | Feb 14 1990 | Material Engineering Technology Laboratory Inc. | Filled and sealed, self-contained mixing container |
5344392, | Sep 28 1990 | EMD Millipore Corporation | Method and apparatus for preparation of solutions from concentrates |
EP399549, | |||
WO9205814, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
May 04 1994 | JONSSON, SVEN | Gambro AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007295 | /0069 | |
May 04 1994 | ANDREN, ANDERS | Gambro AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007295 | /0069 | |
May 05 1994 | KJELLSTRAND, PER | Gambro AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007295 | /0069 | |
May 05 1994 | MARTINSON, EVI | Gambro AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007295 | /0069 | |
May 05 1994 | WIESLANDER, ANDERS | Gambro AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007295 | /0069 | |
May 05 1994 | SVENSSON, EVA | Gambro AB | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007295 | /0069 | |
May 16 1994 | Gambro AB | (assignment on the face of the patent) | / | |||
Nov 17 2006 | Gambro Lundia AB | CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT | SECURITY AGREEMENT | 018552 | /0691 | |
Dec 07 2011 | CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT | Gambro Lundia AB | RELEASE OF SECURITY INTEREST IN PATENTS | 027456 | /0050 |
Date | Maintenance Fee Events |
Dec 29 1999 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
Dec 23 2003 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Jan 04 2008 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Jul 16 1999 | 4 years fee payment window open |
Jan 16 2000 | 6 months grace period start (w surcharge) |
Jul 16 2000 | patent expiry (for year 4) |
Jul 16 2002 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jul 16 2003 | 8 years fee payment window open |
Jan 16 2004 | 6 months grace period start (w surcharge) |
Jul 16 2004 | patent expiry (for year 8) |
Jul 16 2006 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jul 16 2007 | 12 years fee payment window open |
Jan 16 2008 | 6 months grace period start (w surcharge) |
Jul 16 2008 | patent expiry (for year 12) |
Jul 16 2010 | 2 years to revive unintentionally abandoned end. (for year 12) |